8月7日,礼来在公布2025第二季度业绩的同时也更新了其管线信息,有4个临床项目被终止,分别是潜在FIC药物Kv1.3拮抗剂LY3972406治疗银屑病的II期研究,潜在FIC药物SSTR4激动剂mazisotine用于疼痛的II期研究,潜在FIC药物SCAP靶向siRNA药物LY3885125治疗代谢功能障碍相关脂肪肝病(MASLD)的I期研究,衣康酸模拟物LY3839840治疗免疫疾病的I期...
Source Link8月7日,礼来在公布2025第二季度业绩的同时也更新了其管线信息,有4个临床项目被终止,分别是潜在FIC药物Kv1.3拮抗剂LY3972406治疗银屑病的II期研究,潜在FIC药物SSTR4激动剂mazisotine用于疼痛的II期研究,潜在FIC药物SCAP靶向siRNA药物LY3885125治疗代谢功能障碍相关脂肪肝病(MASLD)的I期研究,衣康酸模拟物LY3839840治疗免疫疾病的I期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.